UK government rejects Off-patent Drugs Bill despite widespread support

9 November 2015
ukparliament-big

The Off-patent Drugs Bill was debated in the UK Parliament last week, having been proposed for a second reading by Nick Thomas-Symonds MP.

A Conservative health minister has deliberately blocked a new law to provide cheap and effective drugs for the National Health Service by championing medicines whose patents have expired. Alistair Burt spoke for nearly half an hour to “filibuster” the proposed Off-Patent Drugs Bill, a plan that had cross-party support from backbenchers, reported The Independent newspaper. Mr Burt told MPs: "The reason for resisting what is being suggested is the government believes there is another pathway.

The proposed law would have compelled the government to seek new licences for medicines that were not covered by patents but which could benefit patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics